SHL Medical announces strategic alliance program for autoinjector services
SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has announced the creation of a global Alliance Management program with a selection of solutions providers along the drug delivery value chain.
Driven by its purpose to enable patients’ independence, SHL Medical has been an instrumental partner to several of the world’s leading pharma and biotech companies in pioneering patient-centric, self-injection solutions that support the enhancement of patients’ quality of life. Leveraging its comprehensive in-house development and manufacturing capabilities, SHL Medical provides its customers with end-to-end solutions and services, from design and development to final assembly, labeling, and packaging, as well as connected technologies for digital healthcare.
The Alliance Management program will further strengthen SHL Medical’s vertically integrated business model by facilitating customer engagement with other key players within the drug delivery ecosystem, including primary container providers, CMOs/CDMOs, and various service providers and suppliers of the primary and secondary packaging of the drug product. In its inception, the program will primarily be focused on enhancing SHL Medical’s Molly® modular autoinjector platform offering to ensure that customers have seamless access to a full network of solutions and services that support faster development and simplified supply chain management. The program will allow each of the partners to offer their expert advice, recommendations, and competencies that best cater to the customer’s needs for combination product development.
“Autoinjector development encompasses an intricate network of competencies that each contribute to the successful delivery of a combination product,” said Markus Puusepp, Chief Growth Officer at SHL Medical. “By enhancing the technical integration across various stages of the combination product value chain, these newly formed alliances will continue to generate added value for our customers while fostering a more collaborative culture where partners can leverage and build upon each other’s expertise and knowledge to enhance the drug delivery industry for the betterment of patient care.”
